$Galera Therapeutics, Inc.(GRTX)$ Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a proprietary therapeutics that have the potential to transform radiotherapy (RT) in cancer, announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis (SOM). Avasopasem has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the reduction of SOM induced by RT.BTIG Upgrades to Buy PT 15.
精彩评论